Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation

Published:2021-07 Issue:7 Volume:21 Page:e630-e634
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Sherbenou Daniel,Stalker Margaret,Forsberg Peter,Mark Tomer Martin

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Treatment options for triple-class refractory multiple myeloma;Mikhael;Clin Lymphoma Myeloma Leuk,2020

2. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT);Passweg;Bone Marrow Transplant,2017

3. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

4. Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma;López-Corral;Biol Blood Marrow Transplant,2019

5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed: January 4, 2020.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2021-09